Array Biopharma (ARRY) Stock: Gaining Big On Clinical Results


What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ARRY. In particular, we’re interested in following the ongoing work with regard to the BEACON clinical trial and excited to learn about future results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!


Please enter your comment!
Please enter your name here